The objective of this study was to examine the pharmacokinetics of intravenous dalteparin (Fragmin, Pharmacia-Upjohn, Peapack, NJ) and to assess the accuracy of standard coagulation-based monitoring techniques as an estimate of drug concentration with which to guide dosing. Knowledge of the kinetic behavior of low-molecular-weight heparins (LMWHs) and the possible utility of coagulation times for monitoring may aid in the development of safe and effective dosing algorithms for percutaneous coronary interventions. Twenty normal volunteers were treated at 2-week intervals with each of three intravenous dalteparin doses. Measurement of anti-IIa, anti-Xa, activated partial thromboplastin time (aPTT), activated clotting time (ACT), and low-range ACT was performed at baseline and at seven additional time points over 8 hours. The half-life of intravenous dalteparin is 77 minutes with slight dose-related variation. The aPTT, LR-ACT, and standard ACT are prolonged after dalteparin administration with the increase closely correlated to anti-Xa activity (aPTT, r = 0.85; LR-ACT, r = 0.79). Classification of anticoagulation intensity range using aPTT or LR-ACT in comparison to anti-Xa activity (0.5-0.99, 1.0-1.49, 1.5-2, >2) displays a level of agreement (kappa: aPTT = 0.69, LR-ACT = 0.59) that is comparable to values reported for coagulation time guidance of unfractionated heparin administration. Standard coagulation times are sensitive to the anticoagulant effect of dalteparin with a degree of correlation that suggests their utility for estimating drug concentration during high dose therapy. Trials establishing a relationship between monitoring and clinical efficacy, and the risk/reward of different treatment ranges alone or in combination with GPIIb/IIIa inhibitors and clopidogrel, are necessary.
Rabah MM, et al.Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol1999;84(12):1391.
2.
Young JJ, Kereiakes DJ, Grines CL. Low-molecular-weight heparin therapy in percutaneous coronary intervention: The NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators. J Invas Cardiol2000;12Suppl E:E14.
3.
Collet JP, et al.Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation2001;103(5):658.
4.
Chen WH, et al.Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention. J Invas Cardiol2002;14(8):439.
5.
Choussat R, et al.A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol2002;40(11):1943.
6.
Kereiakes DJ, et al.Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invas Cardiol2001;13(4):272.
7.
Kereiakes DJ, et al.Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J2001;141(3):348.
8.
Marmur JD, et al.The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Coll Cardiol2003;41(3):394.
9.
Boneu B, et al.Pharmacokinetics of heparin and related polysaccharides. Ann NY Acad Sci1989;556:282.
10.
Hirsh J, et al.Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest2001;119(1 Suppl):64S.
11.
Bratt G, Tornebohm E, Widlund L, Lockner D.Low molecular weight heparin (KABI 2165, Fragmin): Pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res1986;42:613.
12.
Dawes J.Comparison of the pharmacokinetics of enoxaparin (Clexane) and unfractionated heparin. Acta Chir Scand1990;556:68.
13.
Le Liboux A, Sanderink G, Grosjean P, et al.Enoxaparin pharmacokinetics and pharmacodynamics after intravenous bolus administration alone and at initiation of a subcutaneous dosing regimen. J Am Coll Cardiol2000;35:373.
14.
Pedersen PC, et al.Pharmacokinetics of a low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers. Thromb Res1991;61(5-6):477.
15.
Follea G, et al.Pharmacokinetic studies of standard heparin and low molecular weight heparin in patients with chronic renal failure. Haemostasis1986;16(2):147.
16.
Troy S, et al.The dose proportionality of the pharmacokinetics of ardeparin, a low molecular weight heparin, in healthy volunteers. J Clin Pharmacol1995;35(12):1194.
17.
Bara L, Samama M.Pharmacokinetics of low molecular weight heparins. Acta Chir Scand1988;543:65.
18.
Boneu B, et al.Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose. Thromb Haemost1998;79(2):338.
19.
Agnelli G, et al.Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. Circulation1995;92(10):2819.
20.
Laforest MD, et al.Pharmacokinetics and biodistribution of technetium 99m labelled standard heparin and a low molecular weight heparin (enoxaparin) after intravenous injection in normal volunteers. Br J Haematol1991;77(2):201.
21.
Bara L, Samama M.Pharmacokinetics of low molecular weight heparins. Acta Chir Scand1990;556:57.
22.
Brieger D, Dawes J.Characterisation of persistent anti-Xa activity following administration of the low molecular weight heparin enoxaparin sodium (Clexane). Thromb Haemost1994;72:275.
23.
Stehle G, Wunder A, Sinn H, et al.Pharmacokinetic properties of LMW-heparintyramine fractions with high or low affinity to antithrombin III in the rat. Semin Thromb Hemost1997;23:31.
24.
Watanabe J, Urano K, Muranishi H, et al.Uptake of low molecular weight fractionated [3H]heparin by rat hepatocytes in the primary culture. Biol Pharm Bull1995;18:443.
25.
Palm M, Mattsson C.Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Thromb Haemost1987;58:932.
26.
Hillegass W, Brott BC, Chapman GD, et al.Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications. Am Heart J2002;144:501.
27.
Chew DP, et al.Defining the optimal activated clotting time during percutaneous coronary intervention: Aggregate results from 6 randomized, controlled trials. Circulation2001;103(7):961.
28.
Hellstern P, et al.Dose response relationships of anticoagulant activities after subcutaneous administration of two low molecular weight heparins in healthy individuals. Thromb Haemost1986;56(2):225.
29.
Ip BK, Thomson AR, Moriarty HT. A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin. Pathology2001;33(3):347.
30.
Azizi M, Veyssier-Belot C, Alhenc-Gelas M, et al.Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. Br J Clin Pharmacol1995;40:577.
31.
Bagge L, et al.Low-molecular-weight heparin (Fragmin) versus heparin for anticoagulation during cardiopulmonary bypass in open heart surgery, using a pig model. Blood Coag Fibrinolysis1994;5(2):265.
32.
Baker B, Adelman MD, Smith PA, Osborn JC. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays. Arch Intern Med1997;157:2475.
33.
Koerber J, Smythe MA, Begle RL, et al.Correlation of activated clotting time and activated partial thromboplastin time to plasma heparin concentration. Pharmacotherapy1999;19:922.
34.
Toulon P, Boutiere B, Horellou MH, Trzeciak MC, Samama MM. Monitoring heparin therapy using activated partial thromboplastin time—results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin. Thromb Haemost1998;80:104.
35.
Smythe MA, et al.Use of the activated partial thromboplastin time for heparin monitoring. Am J Clin Pathol2001;115(1):148.
36.
Bendetowicz AV, Bara L, Samama MM. The inhibition of intrinsic prothrombinase and its generation by heparin and four derivatives in prothrombin poor plasma. Thromb Res1990;58(5):445.
37.
Beguin S, Welzel D, Al Dieri R, Hemker HC. Conjectures and refutations on the mode of action of heparins. The limited importance of anti-factor xa activity as a pharmaceutical mechanism and a yardstick for therapy. Haemostasis1999;29:170.
38.
Biemond BJ, et al.Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis. Circulation1996;93(1):153.
39.
Alban S, Gastpar R.Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins. Thromb Haemost2001;85:824.
40.
Hemker HC, Beguin S.Mode of action of unfractionated and low molecular weight heparins on the generation of thrombin in plasma. Haemostasis1990;20(Suppl 1):81.
41.
Rezaie AR. Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex. Blood2001;97(8):2308.
